drugset / Trial / NCT03899155
Pan Tumor Rollover Study
Phase 2
Recruiting
1500 enrolled
Bristol-Myers Squibb
Clovis Oncology, Inc. · collabExelixis · collabJanssen Pharmaceuticals · collabNovartis · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Timeline
- Start
- 2019-08-09
- Primary completion
- 2029-08-25
- Completion
- 2029-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Cabozantinib | Small molecule | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Nivolumab + Relatlimab | Unknown | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Regorafinib | Unknown | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |
| Subject | Rucaparib | Small molecule | — | — |
| Subject | Sunitinib | Small molecule | — | — |
| Subject | Temozolomide | Small molecule | — | — |
| Subject | Trametinib | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |